GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex® (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome

GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the U.S.

GW Pharmaceuticals Announces the Appointment of Three New Independent Members to its Board of Directors

GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of three new independent members to its Board of Directors, bringing the GW Board to a total of eight members. Joining the Board of Directors today are Catherine Mackey, Alicia Secor and Lord William Waldegrave.

These CEO's Are Using Their Pubco's As A Piggy Bank At The Expense Of YOU The Shareholder

With 2017 coming to a close, we want to highlight an important theme that has accelerated as we approach the end of the year, insider selling.

Although there is nothing wrong with insider selling, timing is everything. If you are an executive and you are receiving a competitive salary, why would you sell stock?

GW Pharmaceuticals Reacquires Full Rights to Develop and Commercialize Sativex® in U.S.

GW Pharmaceuticals plc (Nasdaq:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announces the termination of its previous license agreement with Otsuka Pharmaceutical Co., Ltd. in relation to Sativex® (nabiximols) in the U.S. As a result, GW has now reacquired full ownership of the development and commercialization rights to the product in the U.S.

Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids

Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based treatments, executed a non-exclusive material transfer agreement with Yissum, the technology transfer company of The Hebrew University of Jerusalem, for two synthetic cannabinoids synthesized by Raphael Mechoulam, Ph.D., Professor of medicinal chemistry at the university and Chairman of the Therapix Scientific Advisory Board.

Cara Therapeutics Reports Third Quarter 2017 Financial Results

Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced its financial results for the third quarter ended September 30, 2017.

3 Biotech Stocks Leading The Cannabis Boom

Although the growing and selling of marijuana remains the sexiest opportunity in the legal medical marijuana industry, we continue to see the most potential on the biotech side of the industry.

Biotech companies focused on medical marijuana possess the greatest upside potential as they work to develop treatments derived from marijuana, which can be used to improve daily life for millions of people throughout the world.

Pages